Meta Pixel

News and Announcements

Oz Medicann Group launches new education initiative with University of New England

  • Published September 17, 2018 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Oz Medicann Group (OMG) Pty Ltd is thrilled to announce our new education initiative in conjunction with the University of New England. This program will be run mainly through Educann P/L, a subsidiary with a focus on educating patients and carers, health practitioners, cultivators and the general public. Through this program, called Nucleate, OMG will introduce university students to the medicinal cannabis industry and allow them the opportunity to work toward overcoming industry challenges.

Although the program is offered through the University of New England School of Business, it is open to students from all areas of study as a means of preparing students to assume the wide variety of roles that are vital to the success of this burgeoning industry. Over the course of this 6-week unit, students will participate four weeks of online courses and a 2-day intensive workshop in Armidale, NSW. Two experts, Alice Howard-Vyse and Tida Tippapart, will be working closely with the students on the general side of success in up-and-coming industries, while OMG will be providing specific industry information, including the challenges we currently face.

This program is yet another example of OMG’s commitment to building the new agribusiness of medicinal cannabis here in Australia. In order for this new field to thrive, there must be educated young professionals with the necessary skills and information needed to be industry leaders. By investing in the students of Australia, Oz Medicann Group is investing in the future.

The University of New England is one of the many partnerships we have established. Other partnerships and relationships include:

  • National Institute for Complementary Medicine
  • University of Western Sydney
  • University of New England

One of the main ways OMG strives to attain our goal of “Controlling the chain from seedling to consumer and from researcher to patient” is through our collaborative efforts as mentioned above. To us, collaboration is the first essential step to innovation. Our success as a patient-centric healthcare company relies upon it. For more information on the Nucleate program, visit https://www.une.edu.au/about-une/faculty-of-science-agriculture-business-and-law/unebs/une-
naturally-entrepreneurial/nucleate.

If interested in joining the Oz Medicann group as an investor, team-member, or community member register your interest now.

Register Interest

About Oz Medicann

OZ Medicann is a leading Australian Cannabis and Hemp cultivator that produces medicinal solutions, consumer products and education programs for medical practitioners.

Register Interest

Capital Insights
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be  Attracting Big Pharma’s Attention

Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.

Capital Insights
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship

From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.

Join over 45,000+ sophisticated investors

Join Now